Preparing for the incoming wave of biosimilars in oncology
Wolff-Holz, Elena (Federal Institute for Vaccines and Biomedicines)
Garcia Burgos, Juan (European Medicines Agency)
Giuliani, Rosa (San Camillo Forlanini Hospital)
Befrits, Gustaf (Stockholm County Council)
de Munter, Johan (Universitair Ziekenhuis Gent)
Avedano, Luisa (European Federation of Crohn's & Ulcerative Colitis Associations)
Aitken, Murray (IQVIA Institute for Human Data Science)
Gonzalez-Quevedo, Rosa (European Medicines Agency)
Vyas, Malvika (European Society for Medical Oncology)
De Vries, Elisabeth G. E. (University Medical Center Groningen)
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia)
Universitat Autònoma de Barcelona

Data:	2018
Resum:	With the imminent arrival of oncology biosimilars in the therapeutic paradigm, stakeholders including a clinician, specialist nurse, patient advocate, regulator and economist provide their perspective on optimising the uptake of these new agents in the treatment of cancer. A number of key messages emerge, based on the discussion that took place during a session of the European Society for Medical Oncology's Annual Congress, ESMO Madrid 2017. First, for successful integration of biosimilars into the global healthcare paradigm, informing and educating the full scope of stakeholders, including clinicians, nurses, pharmacists and patients, is primordial. Success is dependent on providing solid evidence and ensuring all voices are heard. Second, for oncology medicines, much can be learnt from the growing experience of approved biosimilars in other disease indications, with success stories for patients, their healthcare providers and healthcare budgets alike. Finally, effective sustainability of the impact on healthcare budgets and the redirection of these savings require education and transparency.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Biosimilars ; Biologicals ; Monoclonal antibodies ; Oncology ; Cancer medicines
Publicat a:	ESMO open, Vol. 3 (september 2018) , ISSN 2059-7029

DOI: 10.1136/esmoopen-2018-000420
PMID: 30245864

8 p, 594.9 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats